I agree that this site is using cookies. You can find further informations here.
X
Selya-Hammer, Carl
16  results:
Search for persons X
?
1

Policy Options for Infliximab Biosimilars in Inflammatory B..:

Husereau, Don ; Feagan, Brian ; Selya-Hammer, Carl
Applied Health Economics and Health Policy.  16 (2018)  3 - p. 279-288 , 2018
Link: https://doi.org/10.1007/..
 
?
2

Development of an enhanced health-economic model and cost-e..:

Selya-Hammer, Carl ; Gonzalez-Rojas Guix, Nuria ; Baldwin, Michael...
Therapeutic Advances in Respiratory Disease.  10 (2016)  5 - p. 391-401 , 2016
Link: https://doi.org/10.1177/..
 
?
3

Co-Administration of PPV23 and Influenza Vaccines in Englan..:

Carl, Selya-Hammer ; Douglas, Fleming ; Yiling, Jiang...
Journal of Vaccines and Immunology.  1 (2015)  1 - p. 043-049 , 2015
Link: https://doi.org/10.17352..
 
?
4

Development of an enhanced health-economic model and cost-e..:

Selya-Hammer, Carl ; Gonzalez-Rojas Guix, Nuria ; Baldwin, Michael...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933617/.  , 2016
Link: http://www.ncbi.nlm.nih...
 
?
5

Development of an enhanced health-economic model and cost-e..:

Selya-Hammer, Carl ; Gonzalez-Rojas Guix, Nuria ; Baldwin, Michael...
Selya-Hammer , C , Gonzalez-Rojas Guix , N , Baldwin , M , Ternouth , A , Miravitlles , M , Rutten-Van Mölken , M , Goosens , L M A , Buyukkaramikli , N & Acciai , V 2016 , ' Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy ' , Therapeutic Advances in Respiratory Disease , vol. 10 , no. 5 , pp. 391-401 . https://doi.org/10.1177/1753465816657272.  , 2016
Link: https://pure.eur.nl/en/p..
 
?
6

Development of an enhanced health-economic model and cost-e..:

Selya-Hammer, Carl ; Gonzalez-Rojas Guix, Nuria ; Baldwin, Michael...
Selya-Hammer , C , Gonzalez-Rojas Guix , N , Baldwin , M , Ternouth , A , Miravitlles , M , Rutten-Van Mölken , M , Goosens , L M A , Buyukkaramikli , N & Acciai , V 2016 , ' Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat ® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy ' , Therapeutic Advances in Respiratory Disease , vol. 10 , no. 5 , pp. 391-401 . https://doi.org/10.1177/1753465816657272.  , 2016
Link: https://pure.eur.nl/en/p..
 
?
7

Development of an enhanced health-economic model and cost-e..:

Selya-Hammer, C. (Carl) ; Gonzalez-Rojas Guix, N. (Nuria) ; Baldwin, M. (Michael)...
http://repub.eur.nl/pub/93383.  , 2016
Link: http://repub.eur.nl/pub/..
 
?
8

Development of an enhanced health-economic model and cost-e..:

Carl Selya-Hammer ; Nuria Gonzalez-Rojas Guix ; Michael Baldwin...
https://doi.org/10.1177/1753465816657272.  , 2016
Link: https://doi.org/10.1177/..
 
?
9

Co-Administration of PPV23 and Influenza Vaccines in Englan..:

Carl Selya-Hammer ; Douglas Fleming ; Yiling Jiang...
https://doi.org/10.17352/jvi.000010.  , 2015
Link: https://doi.org/10.17352..
 
?
10

Selecting Software Packages For Conducting Cost-Effectivene..:

Stephens, TJ ; Selya-Hammer, C ; Gauthier, A
Value in Health.  20 (2017)  9 - p. A754 , 2017
Link: https://doi.org/10.1016/..
 
?
11

The Economic Burden Of Chronic Obstructive Pulmonary Diseas..:

Qu, KQ ; Selya-Hammer, C ; Chew, VC
Value in Health.  19 (2016)  7 - p. A877 , 2016
Link: https://doi.org/10.1016/..
 
?
12

Adapalene 0.1% / Benzoyl Peroxide 2.5% + Doxycycline 200mg ..:

Selya-Hammer, C ; Boval, M ; Patel, S
Value in Health.  18 (2015)  7 - p. A422-A423 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Tioropium+Olodaterol Respimat; Budget Impact In The Uk:

Ternouth, A ; Tebboth, A ; Selya-Hammer, C.
Value in Health.  18 (2015)  7 - p. A496-A497 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Efficacy and Safety of Treatments of Type 2 Diabetes Mellit..:

Pettré, S. ; Selya-Hammer, C. ; Ho, S....
Value in Health.  16 (2013)  7 - p. A433 , 2013
Link: https://doi.org/10.1016/..
 
?
15

PMH20 Metabolic Consequences and Cost-Effectiveness of Asen..:

Selya-Hammer, C. ; Gauthier, A. ; Millar, H.L...
Value in Health.  15 (2012)  7 - p. A337 , 2012
Link: https://doi.org/10.1016/..
 
1-15